

Nebraska Medicaid DUR Board Meeting
Tuesday, March 9, 2010
DRAFT pending approval at May meeting

The Nebraska Medicaid DUR Board met on Tuesday, March 9, 2010 at the Country Inn and Suites in Lincoln.

DUR Board Members in Attendance:

Kevin Borchert, R.P.
Lynn Carlson, R.P.
Elissa Carney, R.P.
Shana Castillo, R.P.
Karsen Duncan, PharmD. Candidate UNMC
Eric Gall, R.P.
Nicole Gillespie, PharmD. Candidate CU
Bruce Houghton, M.D.
Susan Howard, M.D.
David Hutsell, R.P.
Norman Kelley, M.D.
Charlie Moore, R.P.
Marcia Mueeting, R.P., Nebraska DUR Director
Kirk Muffly, M.D.
Phil Vuchetich, R.P.
Robert Wergin, M.D.

Guests in Attendance:

Barbara Mart, Nebraska Medicaid
Barbara Dowd, R.P. First Health Services Corporation
Julie Stukenholtz, PharmD. Candidate UNMC
Jenny Minchow, R.P. Nebraska Medicaid

Public Members in Attendance:

Jim Graves, Bristol-Meyers Squibb
Jeff Hauswald, GlaxoSmithKline
Joe Busby, Lilly
Rose Mullen, Lilly
Bryan Reichmuth, Lilly
Dana Meier, Novartis
Denise Pitner, Novartis
David Chapman, UCB
Michelle Bahl, PharmD. Candidate, UNMC
Amanda Champ, PharmD. Candidate, UNMC
Amanda Gower, PharmD. Candidate, UNMC
Dala Gumeel, PharmD. Candidate, UNMC
Sarah Hulvesher, PharmD. Candidate, UNMC
Ryan Kolarik, PharmD. Candidate, UNMC
Tyler Kozal, PharmD. Candidate, UNMC
Robert Kurasawa, PharmD. Candidate, UNMC
Tyler Lawson, PharmD. Candidate, UNMC
Grant Meier, PharmD. Candidate, UNMC
Hope Mulgrew, PharmD. Candidate, UNMC
Regan Pettijohn, PharmD. Candidate, UNMC
Jennifer Thiele, PharmD. Candidate, UNMC
Mary Venticher, PharmD. Candidate, UNMC

I. Opening and Introductions

The meeting was called to order at 6:37 pm. Introductions were made by the public members attending, DUR Board members, and guests in attendance. The director noted that a copy of the Open Meeting Laws is available on the front table along with a copy of all meeting materials.

II. Declaration of any Conflict of Interest or changes

None

III. Review of Agenda

The director noted that Old Business under Prospective DUR should be removed from the agenda. A motion to accept the agenda as amended was made by Phil Vuchetich with a second from Bob Wergin. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

IV. Review of minutes from January meeting

A motion to accept the minutes as written was made by Elissa Carney with a second from Eric Gall. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

V. Retrospective DUR

A. Current Profile Review

1. Lock Ins

The director reported that profile review in January found 5 patients for lock in evaluation, resulting in 95 letters to providers, with 26 responses and 22 recommended patient for lock in. In February, profile review found 5 patients for evaluation, resulting in 75 letters, 26 responses and 22 recommended patient for lock in.

2. Patients taking methadone with fluoroquinolones

Barbara Dowd reported that 10 letters were sent to prescribers. Five responses were received, with 4 noting the information as useful. Two prescribers planned to discontinue the medication and one had already discontinued the treatment.

3. Patients utilizing multiple providers to obtain controlled substances

Barbara Dowd reported that 129 letters had been sent to prescribers. A 30% response rate was achieved (39) letters. Twenty-four noted that the information was useful and 11 planned to modify therapy.

4. Patients with a diagnosis of Congestive Heart Failure who are not taking an ACE inhibitor, ARB or beta blocker

Barbara Dowd reported that 76 profiles were recently forwarded for review which excluded dual-eligible patients. The director noted that profiles were in the process of being reviewed and found that the majority of patients were not taking any medications consistent with the treatment of heart failure. Discussion resulted in including language in the letters sent to prescribers regarding the possibility of a coding error and a confirmation of the diagnosis on the response form.

B. Recommendations for Future Profile Reviews

The director proposed the following options for future reviews:

1. Patients with diagnoses of diabetes and hypertension not taking either an ACE or ARB.
2. Patients taking duplicative SSRI therapy (of all strengths and dosage forms).
3. Patients taking tamoxifen with a CYP2D6 inhibitor.
4. Patients taking multiple long-acting stimulants for ADHD.

A consensus was reached to perform profile reviews on items 1 and 4.

VI. Prospective DUR

A. Old Business

1. Development of criteria for narcoleptic drugs from profile review

The director provided a handout which detailed the findings of the 198 profiles reviewed and the FDA-approved indications as well as non-approved indications per

MICROMEDEX. Only 32 patients were found to have a diagnosis of narcolepsy, sleep apnea or shift work sleep disorder. There were 105 patients identified to be taking a sedative or hypnotic drug and 138 patients were taking other drugs which can cause drowsiness. A motion was made by Eric Gall with a second from Norman Kelley to recommend Prior Authorization of the narcoleptic class for FDA-labeled indications only, with a 6 month approval period for the indication of shift work sleep disorder and 1 year approval period for all other indications with a letter being sent by Medicaid to the prescribers of the patients who do not have a FDA-approved indication on file informing them of the restriction, allowing 3 months to evaluate the patient's drug therapy. Vote as follows: Borcher-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-no, Howard-yes, Hutsell-no, Kelley-yes, Moore-yes, Muffly-no, Vuchetich-no and Wergin-yes. Motion carried.

2. Development of Prior Authorization criteria for the first generation antihistamines

Barb Mart noted the broad span of cost per prescription in the class and that as the cost for the second-generation antihistamines has decreased, the cost of some of the first generation products has increased. Board members requested additional information, excluding any injectables and unavailable formulations, including the cost per day, grouping the drugs by dosage form and what other state programs are doing in this category to be discussed at the next meeting.

3. DUR Board review of New Drug Products to determine if Prior Authorization is appropriate

a. Lamictal XR

Public comment was offered by Jeff Hauswald. He reported that only the epileptologists and neurologists are being detailed by GSK for the indicated use. The director read the letter of support for Lamictal XR from Dr. Madhavan. Barbara Dowd noted that from March 1, 2009 to February 2010, there were 17 requests for Lamictal XR for 13 patients. Fifteen of the requests were approved. Barb Mart added that many of the approvals were for mentally retarded patients who relied on a caregiver for medication doses. A motion was made by Bob Wergin with a second from Eric Gall to recommend that Prior Authorization remain in place requiring a diagnosis within FDA-approved indications for adjunctive treatment in patients over 13 years of age, a quantity limit of 3 tablets per day of the 200mg strength and 1 per day on all other strengths and a reason why the immediate release is inappropriate. Vote as follows: Borcher- yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

b. Effient

Public comment was offered by Rose Mullen. She noted the indications of Effient and the Triton-TIMI study. A motion was made by Bruce Houghton with a second from Kirk Muffly to recommend removal of the Prior Authorization of Effient. Vote as follows: Borcher-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

c. Vimpat

Public comment was offered by David Chapman. He detailed the cost burden of epilepsy, noting the largest costs were for patients whose disease was not in control. He noted the novel mechanism of action for lacosamide and that there are no known drug-drug interactions. Barbara Dowd reported that there had been 94 approvals for 51 patients and there were no denials. Barb Mart explained that programming at the point of sale was recently placed on Vimpat, requiring a seizure diagnosis, to prevent off-label use for diabetic neuropathy. A motion was made by Charlie Moore with a second from Bruce Houghton to recommend removal of the Prior Authorization of Vimpat, with an age limit of 17 years or greater and a quantity limit of 2 tablets per day. Vote as follows: Borcher-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

2. Request from the Department to develop criteria for the Oral Antifungals: flucytosine, itraconazole, posaconazole and voriconazole per P & T Committee discussion

The director noted that the NCCN Practice Guidelines and the consideration of the drug of choice would result in the addition to the current criteria of MDS, AML and Graft Versus Host Disease for criteria to receive posaconazole and C. Krusei, Blastomycosis, MDS, AML and Graft Versus Disease for the criteria to receive voriconazole without a trial of a preferred drug. It was recommended by the Board that the Department notify providers who were most likely to prescribe the non-preferred drugs of the criteria. A motion was made by Bruce Houghton with a second from to recommend modifying the current as outlined with a second from Kirk Muffly. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

3. Annual Review of Prior Authorization for Symlin

The director noted that she is not aware of any changes to the indications for Symlin. A motion was made by Shana Castillo with a second from Phil Vuchetich to recommend that the Prior Authorization remain in place with no changes. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-yes, Vuchetich-yes and Wergin-yes. Motion carried.

VII. Special Requests from the Department

None

VIII. Future Meeting Dates

May 11

July 13

September 14

November 9

IX. Concerns and Comments from:

Board

None

Director

None

State Representatives

None

X. Adjournment

A motion to adjourn at 8:44 pm was made by Kevin Borchert with a second from Bob Wergin. Vote as follows: Borchert-yes, Carlson-yes, Carney-yes, Castillo-yes, Gall-yes, Houghton-yes, Howard-yes, Hutsell-yes, Kelley-yes, Moore-yes, Muffly-no, Vuchetich-yes and Wergin-yes. Motion carried.